Home > Healthcare > Medical Devices > Therapeutic Devices > Congestive Heart Failure (CHF) Treatment Devices Market

Congestive Heart Failure (CHF) Treatment Devices Market Share

Report ID: GMI7994
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Congestive Heart Failure Treatment Devices Market Share

The congestive heart failure treatment devices industry is competitive in nature, with several large multinationals, small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies are among a key market strategy. Some of the leading industry players including Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic plc, among others have a notable presence in the market.

Congestive Heart Failure Treatment Devices Market Companies

Some of the eminent market participants operating in the congestive heart failure treatment devices industry include:

Abbott Laboratories
Biotronik SE & Co. KG
Boston Scientific Corporation
Koninkilijke Philips N.V.
Lepu Medical Technology Co. Ltd.
LivaNova PLC
MEDICO S.p.A.
Medtronic plc
MicroPort Scientific Corporation
OSCOR Inc.
Schiller AG
Shree Pacetronix Ltd.
St. Jude Medical, Inc.
Stryker Corporation
Terumo Corporation

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Congestive heart failure (CHF) treatment devices industry size was USD 23.5 billion in 2023 and is anticipated to surpass USD 41.7 billion by 2032 owing to the rising prevalence of heart failure and cardiovascular diseases and an increasing awareness regarding heart failure treatment.

The defibrillators segment accounted for 52.6% share of the CHF treatment devices industry in 2023 and is projected to grow at a robust pace through 2032 attributed to their extensive use in hospital settings, emergency departments, and cardiac care units.

North America congestive heart failure treatment devices industry size was USD 10.3 billion in 2023 and is set to exhibit robust growth through 2032 driven by the presence of leading industry players, an increasing demand for cardiovascular devices.

Leading congestive heart failure treatment device firms are Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Koninkilijke Philips N.V., LivaNova PLC, Medtronic plc, MicroPort Scientific Corporation, OSCOR Inc., St. Jude Medical, Inc., Stryker Corporation, and Terumo Corporation.